title: Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome.
abstract: BACKGROUND
  Molecular Adsorbents Recirculating System (MARS) is a new promising artificial liver support therapy, the aim of this study was to assess the effectiveness of MARS to remove nitrous oxide (NO) and cytokines in severe liver failure patients with multiple organ dysfunction syndrome (MODS).
  
  
  METHODS
  Sixty single MARS treatments were performed with length of 6-24 h on 24 severe liver failure patients (18 males/6 females) with MODS.
  
  
  RESULTS
  The MARS therapy was associated with a significant removal of NO and certain cytokines such as TNF-alpha, IL-6, IL-8, and INF-gamma, together with marked reduction of other non-water-soluble albumin bound toxins and water-soluble toxins, these were associated with a improvement of the patients' clinical conditions including hepatic encephalopathy, deranged hemodynamic situation and as well as renal and respiratory function, thus resulted into marked decrease of Sequential Organ Failure Assessment (SOFA) score and improved outcome: nine patients were able to be discharged from the hospital or bridged to successful liver transplantation, the overall survival of 24 patients was 37.5%.
  
  
  CONCLUSIONS
  We can confirm the positive therapeutic impact and safety to use MARS on liver failure patients with MODS associated with elevated levels of NO and cytokines.
authors.affiliation: ICU & Artificial Liver Support Center, Beijing DiTan Hospital, Beijing, PR China.
authors.forename: Li-Min
authors.initials: LM
authors.lastname: Guo
authors.forename: Jing-Yuan
authors.initials: JY
authors.lastname: Liu
authors.forename: Dao-Zhen
authors.initials: DZ
authors.lastname: Xu
authors.forename: Bao-Shun
authors.initials: BS
authors.lastname: Li
authors.forename: Hao
authors.initials: H
authors.lastname: Han
authors.forename: Ling-Hang
authors.initials: LH
authors.lastname: Wang
authors.forename: Wei-Yan
authors.initials: WY
authors.lastname: Zhang
authors.forename: Lian-He
authors.initials: LH
authors.lastname: Lu
authors.forename: Xia
authors.initials: X
authors.lastname: Guo
authors.forename: Feng-Xia
authors.initials: FX
authors.lastname: Sun
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Zhang
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Liu
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Zhang
authors.forename: Yun
authors.initials: Y
authors.lastname: Yao
authors.forename: Zhong-Ping
authors.initials: ZP
authors.lastname: He
authors.forename: Min-Min
authors.initials: MM
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D017114:Liver Failure, Acute / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000097:blood / Q000628:therapy*; D009609:Nitrous Oxide / Q000097:blood*; D006435:Renal Dialysis; D012720:Severity of Illness Index; D016060:Sorption Detoxification; D014118:Toxins, Biological / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D016207:Cytokines; D015850:Interleukin-6; D016209:Interleukin-8; D014118:Toxins, Biological; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D009609:Nitrous Oxide